Dostarlimab
Monoclonal antibody
Also known as TSR-042
Evidence outlook
Approved: Endometrial Cancer, Rectal Cancer [accelerated]
Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Non-Small Cell Lung Cancer · Phase 3
Also approved (3)
- JEMPERLI (dostarlimab-gxly): adults with stage II or III mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced rectal cancer (accelerated approval)
- Mismatch Repair Deficient Recurrent or Advanced Solid Tumors JEMPERLI, as a single agent, is indicated for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA‑authorized test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration ( 2.1 )] . This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies ( 14.3 )] . Continued approval for this indication may be contingent upon verification
- Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
RUBY NCT03981796 · Neoplasms Registry: NCT03981796 | 3 | Parts 1 and 2: Progression-Free Survival (PFS) - investigator assessment (Up to 6 years); Part 1: Overall survival (Up to 6 years) 2026-11-26 | In progress: results expected 26 Nov 2026 | not yet graded | link ↗ |
View 2 more trials
NCT04165772 NCT04165772 · Endometrial Cancer Registry: NCT04165772 | 2 | Pathologic complete response (pCR) or complete clinical response (cCR) at 12 months 2026-11-30 | Label-reported response: The cCR12 rate was 93% (95% CI: 82%, 99%) and the ORR was 100% (95% CI: 93%, 100%). | not yet graded | link ↗ |
GARNET NCT02715284 · Neoplasms Registry: NCT02715284 | 1 | Part 1: Number of participants with treatment emergent AEs (TEAEs) (Up to 2 years); Part 1: Number of participants with immune mediated AEs of interest (Up to 2 years); Part 1: Number of participants with abnormal hematology parameters (Up to 2 years); Part 1: Number of participants with abnormal clinical chemistry parameters (Up to 2 years); Part 1, Part 2A, and Part 2B: Number of participants with a change from baseline in urinalysis parameters (Up to 2 years); Part 1, Part 2A, and Part 2B: Number of participants with a change from baseline in vital signs (Up to 2 years); Part 1: Number of participants with abnormal electrocardiogram (ECG) parameters (Up to 2 years); Part 1: Number of participants receiving concomitant medications (Up to 2 years); Part 2A: Number of participants with TEAEs (Up to 2 years); Part 2A: Number of participants with immune mediated AEs of interest (Up to 2 years); Part 2A: Number of participants with abnormal hematology parameters (Up to 2 years); Part 2A: Number of participants with abnormal clinical chemistry parameters (Up to 2 years); Part 2A: Number of participants with abnormal ECG (Up to 2 years); Part 2A: Number of participants receiving concomitant medications (Up to 2 years); Part 2B: Number of participants with TEAEs (Up to 2 years); Part 2B: Number of participants with immune related AEs of interest (Up to 2 years); Part 2B: Number of participants with abnormal hematology parameters (Up to 2 years); Part 2B: Number of participants with abnormal clinical chemistry parameters (Up to 2 years); Part 2B: Number of participants with abnormal ECG parameters (Up to 2 years); Part 2B: Number of participants receiving concomitant medications (Up to 2 years); Part 2B: Cohort A1 Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Up to 2 years); Part 2B: Cohort F ORR by RECIST version 1.1 (Up to 2 years); Part 2B: Cohort A2 ORR by RECIST version 1.1 (Up to 2 years); Part 2B: Cohort G ORR by RECIST version 1.1 (Up to 2 years); Part 2B: Cohort E ORR by immune related Response Evaluation Criteria in Solid Tumors per irRECIST (Up to 2 years); Part 2B: Cohort A1 Duration of response (DOR) (Up to 2 years); Part 2B: Cohort F Duration of response (DOR) (Up to 2 years); Part 2B: Cohort A2 Duration of response (DOR) (Up to 2 years) 2026-05-18 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (55)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Nivolumab, Opdivo Qvantig, Pembrolizumab, Pembrolizumab berahyaluronidase alfa and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Endometrial Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dostarlimab: this drug | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023). | |
| Fruquintinib (Fruzaqla / Elunate) | Phase 3 | Small molecule | VEGFR1/2/3 | not yet graded | No reviewed efficacy summary in this indication | |
| Iparomlimab (QL1604) | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| PF-08634404 | Phase 3 | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Puxitatug Samrotecan | Phase 3 | Antibody–drug conjugate | B7-H4 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Rinatabart Sesutecan (Rina-S) | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Govitecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Selinexor | Phase 3 | Small molecule | XPO1 (exportin-1) | not yet graded | No reviewed efficacy summary in this indication | |
| Sotiburafusp Alfa | Phase 3 | Multispecific antibody | PD-L1 / VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Pamirtecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Envafolimab | Phase 2 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Serabelisib | Phase 2 | Small molecule | PI3K alpha (inhibitor) | Weak signal | No reviewed efficacy summary in this indication | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Bmab1700 | Phase 1(overall) | Monoclonal antibody | PD-1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| IMGN-151 | Phase 1 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
17 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(44 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Dostarlimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (7)
November 2026 (4)
What to watch
What to watch
What to watch
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (16)
January 2027 (2)
February 2027 (2)
March 2027 (4)
What to watch
What to watch
What to watch
What to watch
April 2027 (2)
What to watch
What to watch
June 2027 (2)
August 2027 (1)
What to watch
October 2027 (2)
December 2027 (1)
What to watch
2028 (10)
February 2028 (1)
What to watch
June 2028 (3)
July 2028 (3)
What to watch
What to watch
What to watch
September 2028 (1)
What to watch
October 2028 (2)
What to watch
2029 (4)
2030 (7)
March 2030 (2)
April 2030 (1)
What to watch
June 2030 (1)
What to watch
August 2030 (1)
What to watch
November 2030 (1)
What to watch
December 2030 (1)
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent